Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in December 2008 on request of the Sponsor.
On 9 July 2001, orphan designation EU/3/01/046 was granted by the European Commission to Laboratoires LAPHAL, France, for thalidomide for the treatment of graft versus host disease.
The sponsorship was transferred to Laphal Developpement in September 2002. Laphal Developpement changed name to Pharmion Developpement in 2004 and Pharmion Developpement changed name to Pharmion France in 2007.
Treatment of graft-versus-host disease
|Orphan designation status||
|EU designation number||
|Date of designation||
6/8 Boulevard Haussmann
Telephone : +33 1 42 99 97 02
Telefax : +33 1 42 99 97 01
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: